Medidata’s Cloud-Based Platform Powers Next-Generation Immunotherapy Vaccine Trial In Australia

NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Admedus Ltd (ASX:AHZ), a specialist healthcare company that delivers innovative medical technologies and devices, has adopted its industry-leading cloud technology. The Australian-based listed company is leveraging the Medidata Clinical Cloud® platform to bring speed, efficiencies and enhanced decision-making to its clinical development of a therapeutic vaccine for genital herpes (HSV-2), aimed at activating a T-cell response against the virus to benefit sufferers.

Help employers find you! Check out all the jobs and post your resume.